🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Xin Gao

ORCID: 0000-0002-7383-6453

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 5 papers. Top paper: “US Food and Drug Administration Approval Summary: Capivasertib With Fulvestrant for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Locally Advanced or Metastatic Breast Cancer With PIK3CA / AKT1 / PTEN Alterations”.

US Food and Drug Administration Approval Summary: Capivasertib With Fulvestrant for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Locally Advanced or Metastatic Breast Cancer With PIK3CA / AKT1 / PTEN Alterations

Journal of Clinical Oncology(2024)10.1200/jco.24.00427

N/A

0.978DataRank · unranked

41 citations

James Buturla, Christy Osgood, Xin Gao, Wei Chen, Tiffany K. Ricks +14 more

FDA Approval Summary: Belzutifan for Patients with Advanced Renal Cell Carcinoma

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-1199

N/A

0.505DataRank · unranked

28 citations

Brian L. Heiss, Hee‐Koung Joeng, Chana Weinstock, Xin Gao, William F. Pierce +8 more

FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-1393

N/A

0DataRank · unranked

32 citations

William F. Maguire, Chana Weinstock, Hui Zhang, Xin Gao, Fang Li +14 more

FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-3738

N/A

0DataRank · unranked

18 citations

Daniel Lee, Chana Weinstock, Xin Gao, Catharine C. Bulik, Sundeep Agrawal +9 more

False-Positive Circulating Tumor DNA Results Do Not Explain Lack of Efficacy for PARP Inhibitors in Patients With Castration-Resistant Prostate Cancer Harboring ATM and CHEK2 Mutations

JCO Precision Oncology(2024)10.1200/po.24.00354

N/A

0DataRank · unranked

2 citations

Jianjin Xu, Hee‐Koung Joeng, Chana Weinstock, Brian L. Heiss, William F. Maguire +10 more